# DL03 (NCT04686305)

> Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04686305
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions: T-DXd; Durvalumab; Cisplatin; Carboplatin; Pemetrexed; Volrustomig; Rilvegostomig
- Enrollment: 304
- Primary outcome: Frequency of AEs and SAEs

## Indexed commentary on DL03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 15
- YouTube: 10
- X threads: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dl03-nct04686305

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04686305", "email": "<work email>"}; the inbox owner confirms by the emailed link.